Dong Xiang, Chang Geng, Ji Xiao-Fei, Tao Ding-Bo, Wang Ying-Xin
Department of Neurology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, P.R. China.
PLoS One. 2014 Apr 11;9(4):e94845. doi: 10.1371/journal.pone.0094845. eCollection 2014.
The aim of the study was to assess the relationship between insulin-like growth factor I (IGF-I) serum levels and acute ischemic stroke (AIS) in a Chinese population.
All consecutive patients with first-ever AIS from August 1, 2011 to July 31, 2013 were recruited to participate in the study. The control group comprised 200 subjects matched for age, gender, and conventional vascular risk factors. IGF-I serum levels were determined by chemiluminescence immunoassay. The National Institutes of Health Stroke Scale (NIHSS) score was assessed on admission blinded to serum IGF-I levels.
The median serum IGF-1 levels were significantly (P = 0.011) lower in AIS patients (129; IQR, 109-153 ng/mL) compared with control cases (140; IQR, 125-159 ng/mL). We found that an increased risk of AIS was associated with IGF-I levels ≤135 ng/mL (unadjusted OR: 4.17; 95% CI: 2.52-6.89; P = 0.000). This relationship was confirmed in the dose-response model. In multivariate analysis, there was still an increased risk of AIS associated with IGF-I levels ≤135 ng/mL (OR: 2.16; 95% CI:1.33-3.52; P = 0.002) after adjusting for possible confounders.
Lower IGF-I levels are significantly related to risk of stroke, independent from other traditional and emerging risk factors, suggesting that they may play a role in the pathogenesis of AIS. Thus, strokes were more likely to occur in patients with low serum IGF-I levels in the Chinese population; further, post-ischemic IGF-I therapy may be beneficial for stroke.
本研究旨在评估中国人群中胰岛素样生长因子I(IGF-I)血清水平与急性缺血性卒中(AIS)之间的关系。
纳入2011年8月1日至2013年7月31日期间所有首次发生AIS的连续患者参与本研究。对照组由200名年龄、性别及传统血管危险因素相匹配的受试者组成。采用化学发光免疫分析法测定IGF-I血清水平。在对血清IGF-I水平不知情的情况下于入院时评估美国国立卫生研究院卒中量表(NIHSS)评分。
与对照组(140;四分位间距,125 - 159 ng/mL)相比,AIS患者的血清IGF-1水平中位数显著更低(P = 0.011)(129;四分位间距,109 - 153 ng/mL)。我们发现,IGF-I水平≤135 ng/mL与AIS风险增加相关(未校正比值比:4.17;95%置信区间:2.52 - 6.89;P = 0.000)。这种关系在剂量反应模型中得到证实。在多变量分析中,校正可能的混杂因素后,IGF-I水平≤135 ng/mL仍与AIS风险增加相关(比值比:2.16;95%置信区间:1.33 - 3.52;P = 0.002)。
较低的IGF-I水平与卒中风险显著相关,独立于其他传统和新出现的危险因素,提示其可能在AIS发病机制中起作用。因此,在中国人群中,血清IGF-I水平低的患者更易发生卒中;此外,缺血后IGF-I治疗可能对卒中有益。